Panacea Biotec ended higher by 7.2% at Rs 73 in trades on Thursday on launch of its new facility in Himachal Pradesh for the production of anti-cancer products.
Panacea Biotec plans to scale up production of anti-cancer products with the commissioning of its new facility in Himachal Pradesh. The new oncology facility will entail an annual production capacity of around 1.2 million vials. The unit enjoys various fiscal incentives like excise duty exemption, sales tax concession etc. The total project cost of setting up the plant is around Rs 55 crore.
The stock opened at Rs 69 and touched the high of Rs 76 in intra-day deals today. As many as 7,169 shares changed hands compared to its two-week average of 7,169 shares.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app